Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 7Completed 4Active not recruiting 2Terminated 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Breast Neoplasms 33Neoplasms 31Melanoma 24Neoplasm Metastasis 22Leukemia, Myeloid, Acute 21Colorectal Neoplasms 18Prostatic Neoplasms 17Multiple Myeloma 17Lung Neoplasms 17Ovarian Neoplasms 14Myelodysplastic Syndromes 13Squamous Cell Carcinoma of Head and Neck 12Recurrence 12Lymphoma, Non-Hodgkin 12Carcinoma, Renal Cell 11Uterine Cervical Neoplasms 10Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Glioblastoma 10Brain Neoplasms 10Carcinoma, Hepatocellular 9Stomach Neoplasms 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Lymphoma 7Hodgkin Disease 7Head and Neck Neoplasms 7Glioma 7

Interventions

empagliflozin 1Carvedilol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Heart Failure × 90 days × Clear all
NCT06844669 2026-05-13

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Washington University School of Medicine

Phase 2 Terminated
7 enrolled
Breast

Breast Neoplasms, Heart Failure, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡